SCARNA7: A Potential Drug Target and Biomarker (G677767)

Target Name: SCARNA7

NCBI ID: G677767

SCARNA7

Other Name(s): Small Cajal body-specific RNA 7 | small Cajal body-specific RNA 7 | U90

SCARNA7: A Potential Drug Target and Biomarker

Small Cajal body-specific RNA 7 (SCARNA7) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. SCARNA7 is a key regulator of gene expression in the Cajal-Retzius system, a protein complex that plays a role in the regulation of muscle contractions in the heart. The Cajal-Retzius system is also known as the cardiac myofibrillation gene regulatory complex (CMR-GRC), and it is a complex of genes that are involved in the regulation of the heart's electrical activity and muscle contractions.

Studies have shown that SCARNA7 is highly expressed in various tissues and organs, including heart, muscle, and brain. It is also highly expressed in cancer tissues, which suggests that it may be a potential biomarker for cancer. Additionally, SCARNA7 has been shown to play a role in the regulation of cell apoptosis, which is a process by which cells undergo programmed cell death. This suggests that it may also be a potential drug target for diseases that are characterized by uncontrolled cell growth and apoptosis.

In addition to its potential drug target and biomarker properties, SCARNA7 is also of interest as a potential therapeutic agent for a variety of diseases. For example, it has been shown to be downregulated in various diseases, including cancer, heart disease, and neurological disorders. This suggests that increasing the expression of SCARNA7 may have therapeutic benefits. Additionally, because SCARNA7 is highly expressed in cancer tissues, it may be a potential target for cancer therapies that target RNA-based processes.

The discovery and characterization of SCARNA7 as a potential drug target and biomarker has important implications for the development of new therapies for a variety of diseases. Further research is needed to fully understand the role of SCARNA7 in the regulation of gene expression and to determine its potential as a drug target and biomarker. However, the identification of SCARNA7 as a potential drug target and biomarker is a promising start in this direction, and further research is likely to uncover its full potential in the future.

Protein Name: Small Cajal Body-specific RNA 7

The "SCARNA7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCARNA7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets